Brief Summary
The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).
Intervention / Treatment
- Drug: Cilta-cel
- Drug: Talquetamab
- Drug: Daratumumab
- Drug: Lenalidomide
- Drug: Dexamethasone
Inclusion Criteria:
- Documented diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of MM according to the IMWG diagnostic criteria and is defined as a measurable disease at screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening
- Cohorts 1 and 3: Received at least 3 prior lines of antimyeloma therapy and have undergone greater than or equal to (>=) 1 complete cycle of the therapy. Cohort 2: Be newly diagnosed MM and considered ineligible for high-dose chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells with autologous stem cell transplanta procedure that involves replacing unhealthy blood-forming cells (stem cells) with healthy stem cells (ASCT)
- Cohorts 1 and 3: Documented evidence of progression of disease (PD) or failure to achieve a response to the last line of therapy
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status score of 0 or 1
- Participant of childbearing potential (POCBP) must have a negative pregnancy test using a highly sensitive β-human chorionic gonadotropin (hCG) serum pregnancy test at screening.